Schlieren (Zürich), Switzerland, July 31, 2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND OR MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA").
Kuros Biosciences announces full exercise of over-allotment option
Kuros Biosciences today announced that the over-allotment option granted to Zürcher Kantonalbank in connection with the capital increase has been exercised in full on July 28, 2017. Including the 200,000 shares placed in connection with the over-allotment option, Kuros has sold a total of 1,351,606 registered shares in the rights and share offering.
Based on the issue price of CHF 12.50 per share, Kuros received total gross proceeds of CHF 16.9 million. The new shares for the exercise of the over-allotment option will be issued out of existing authorized share capital. After completion of the capital increase, total share capital of Kuros amounts to CHF 7,800,929 consisting of 7,800,929 registered shares. The first trading day of the new shares is expected to be on or around August 7, 2017.
Zürcher Kantonalbank, goetzpartners and Octavian were acting as Joint Placement Agents for Kuros in the offering.
Details on stabilization in accordance with Art. 126 of the Financial Market Infrastructure Ordinance are available from Kuros' website under www.kuros.ch/investors/regulatory-filings.html.
Provider | Channel | Contact | ||
---|---|---|---|---|
Tensid EQS Ltd., Switzerland www.tensid.ch |
newsbox.ch www.newsbox.ch |
Provider/Channel related enquiries marco@tensid.ch +41 41 763 00 50 |